rotigotine vs Rotigotine (LY03003)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: Dopamine receptors · full Parkinson's Disease pipeline

rotigotine · Neupro

Marketed by UCB and partners

Approved in Parkinson's Diseasesmall molecule
Weak signal

NCT00244387 · Phase 3 · completed

Although the registry reports a randomized, double-blind design with 506 participants, it lists no comparator arm, so the treatment cannot be evaluated against another treatment or placebo from the available record. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score (baseline, 16 weeks after dosing): UPDRS Part III change at 16 weeks, rotigotine vs placebo: -6.4 ± 1.2 (95% CI -8.7 to -4.1; p<0.001); non-inferior to ropinirole (n=420). (met)

Result source: NCT01628926

Rotigotine (LY03003) · Jinyouping

Marketed by Luye Pharma Group

Phase 3 in Parkinson's Diseasesmall molecule
Partial signal

NCT04571164 · Phase 3 · completed

The Phase 3 trial randomised 294 patients with early Parkinson's disease (147 per arm) to LY03003 or placebo with quadruple masking. A conference abstract reports that the primary endpoint, change in UPDRS II+III at 24 weeks, favoured LY03003 (-11.8 vs -5.6, P<0.001). The registry has no posted results and no peer-reviewed paper was found.

Result from a conference abstract (International Congress of Parkinson's Disease and Movement Disorders, 2025), not from the registry or a peer-reviewed publication.

Reported efficacy

Change from baseline to the end of the treatment period in the Unified Parkinson's Disease Rating Scale(UPDRS)part(Ⅱ+Ⅲ)Total Score (From baseline to the end of the double-blind dose maintenance period at 24weeks): Change from baseline in UPDRS Part II+III total score: LY03003 -11.8 vs placebo -5.6 (P<0.001) (met)

Result source: NCT04571164

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointrotigotineRotigotine (LY03003)
OFF time, change-2.1 vs -0.7−1.4 vs placebowk 12 · n 54NCT01628848—Not posted · NCT04571164
ON time without troublesome dyskinesia, change—Not posted · NCT00243971—Not posted · NCT04571164
UPDRS Part III, change-10.9 vs -4.5−6.4 vs placebowk 16 · n 164NCT01628926
3 other results
  • -9.9 vs -5.3 wk 10 · n 164 · Phase 3 · secondary NCT01628926
  • -9.7 vs -5.5 wk 8 · n 164 · Phase 3 · secondary NCT01628926
  • -10.1 vs -4.4 wk 12 · n 86 · Phase 2 · primary NCT01628848
—Not posted · NCT04571164
MDS-UPDRS Part II, change—Not posted · NCT00243971—Not posted · NCT04571164

OFF time, change

rotigotine
-2.1 vs -0.7−1.4 vs placebowk 12 · n 54NCT01628848
Rotigotine (LY03003)
—Not posted · NCT04571164

ON time without troublesome dyskinesia, change

rotigotine
—Not posted · NCT00243971
Rotigotine (LY03003)
—Not posted · NCT04571164

UPDRS Part III, change

rotigotine
-10.9 vs -4.5−6.4 vs placebowk 16 · n 164NCT01628926
3 other results
  • -9.9 vs -5.3 wk 10 · n 164 · Phase 3 · secondary NCT01628926
  • -9.7 vs -5.5 wk 8 · n 164 · Phase 3 · secondary NCT01628926
  • -10.1 vs -4.4 wk 12 · n 86 · Phase 2 · primary NCT01628848
Rotigotine (LY03003)
—Not posted · NCT04571164

MDS-UPDRS Part II, change

rotigotine
—Not posted · NCT00243971
Rotigotine (LY03003)
—Not posted · NCT04571164
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. rotigotine: 4 of 4 rows · Rotigotine (LY03003): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricrotigotineRotigotine (LY03003)
Dropout rate
15.5%a
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 33 more results
19%
NCT01523301 · Phase 4 · registry result, not featured evidence
9.8%high dose
NCT01782222 · Phase 4 · registry result, not featured evidence
26.8%low dose
NCT01782222 · Phase 4 · registry result, not featured evidence
5.7%
NCT01744496 · Phase 4 · registry result, not featured evidence
9.2%
NCT01711866 · Phase 4 · registry result, not featured evidence
19.6%
NCT01300819 · Phase 4 · registry result, not featured evidence
21.4%
NCT00594464 · Phase 4 · registry result, not featured evidence
8%
NCT01646255 · Phase 3 · registry result, not featured evidence
8.9%
NCT01646268 · Phase 3 · registry result, not featured evidence
12.2%
NCT01723904 · Phase 3 · registry result, not featured evidence
20.2%
NCT01631825 · Phase 3 · registry result, not featured evidence
14.9%8 mg/24 hr
NCT00522379 · Phase 3 · registry result, not featured evidence
21.2%6 mg/24 hr
NCT00522379 · Phase 3 · registry result, not featured evidence
21.5%4 mg/24 hr
NCT00522379 · Phase 3 · registry result, not featured evidence
21.8%2 mg/24 hr
NCT00522379 · Phase 3 · registry result, not featured evidence
12.6%
NCT00474058 · Phase 3 · registry result, not featured evidence
52.2%
NCT00501969 · Phase 3 · registry result, not featured evidence
51.1%
NCT00505687 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT00594386 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT00599196 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT00594165 · Phase 3 · registry result, not featured evidence
21.8%
NCT00593606 · Phase 3 · registry result, not featured evidence
34.3%
NCT01628965 · Phase 2/3 · registry result, not featured evidence
16.7%
NCT00537485 · Phase 2/3 · registry result, not featured evidence
28.5%
NCT01631812 · Phase 2 · registry result, not featured evidence
13.8%
NCT01628848 · Phase 2 · registry result, not featured evidence
0%1 Puff
NCT00296192 · Phase 2 · registry result, not featured evidence
0%2 Puffs
NCT00296192 · Phase 2 · registry result, not featured evidence
0%3 Puffs
NCT00296192 · Phase 2 · registry result, not featured evidence
0%4 Puffs
NCT00296192 · Phase 2 · registry result, not featured evidence
11.6%Advanced Parkinson's Disease
NCT01634243 · Phase 2 · registry result, not featured evidence
28.6%Early-stage Parkinson's Disease
NCT01634243 · Phase 2 · registry result, not featured evidence
—
NCT00292227 · Phase 1 · registry result, not featured evidence
—
Discontinued due to AEs
7.7%a
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 33 more results
13.6%
NCT01523301 · Phase 4 · registry result, not featured evidence
7.3%high dose
NCT01782222 · Phase 4 · registry result, not featured evidence
12.2%low dose
NCT01782222 · Phase 4 · registry result, not featured evidence
2.9%
NCT01744496 · Phase 4 · registry result, not featured evidence
2.3%
NCT01711866 · Phase 4 · registry result, not featured evidence
12.1%
NCT01300819 · Phase 4 · registry result, not featured evidence
—
NCT00594464 · Phase 4 · registry result, not featured evidence
4.6%
NCT01646255 · Phase 3 · registry result, not featured evidence
4.8%
NCT01646268 · Phase 3 · registry result, not featured evidence
5.6%
NCT01723904 · Phase 3 · registry result, not featured evidence
13.1%
NCT01631825 · Phase 3 · registry result, not featured evidence
5.3%8 mg/24 hr
NCT00522379 · Phase 3 · registry result, not featured evidence
11.5%6 mg/24 hr
NCT00522379 · Phase 3 · registry result, not featured evidence
14%4 mg/24 hr
NCT00522379 · Phase 3 · registry result, not featured evidence
11.9%2 mg/24 hr
NCT00522379 · Phase 3 · registry result, not featured evidence
5.8%
NCT00474058 · Phase 3 · registry result, not featured evidence
19.2%
NCT00501969 · Phase 3 · registry result, not featured evidence
25.8%
NCT00505687 · Phase 3 · registry result, not featured evidence
26.4%
NCT00594386 · Phase 3 · registry result, not featured evidence
24.4%
NCT00599196 · Phase 3 · registry result, not featured evidence
24%
NCT00594165 · Phase 3 · registry result, not featured evidence
10.5%
NCT00593606 · Phase 3 · registry result, not featured evidence
21%
NCT01628965 · Phase 2/3 · registry result, not featured evidence
11.1%
NCT00537485 · Phase 2/3 · registry result, not featured evidence
19.2%
NCT01631812 · Phase 2 · registry result, not featured evidence
10.3%
NCT01628848 · Phase 2 · registry result, not featured evidence
—1 Puff
NCT00296192 · Phase 2 · registry result, not featured evidence
—2 Puffs
NCT00296192 · Phase 2 · registry result, not featured evidence
—3 Puffs
NCT00296192 · Phase 2 · registry result, not featured evidence
—4 Puffs
NCT00296192 · Phase 2 · registry result, not featured evidence
11.6%Advanced Parkinson's Disease
NCT01634243 · Phase 2 · registry result, not featured evidence
23.8%Early-stage Parkinson's Disease
NCT01634243 · Phase 2 · registry result, not featured evidence
—
NCT00292227 · Phase 1 · registry result, not featured evidence
—
Serious AEs
4.2%a
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 33 more results
3.3%
NCT01523301 · Phase 4 · registry result, not featured evidence
2.4%high dose
NCT01782222 · Phase 4 · registry result, not featured evidence
4.9%low dose
NCT01782222 · Phase 4 · registry result, not featured evidence
5.7%
NCT01744496 · Phase 4 · registry result, not featured evidence
1.1%
NCT01711866 · Phase 4 · registry result, not featured evidence
3.6%
NCT01300819 · Phase 4 · registry result, not featured evidence
28.6%
NCT00594464 · Phase 4 · registry result, not featured evidence
3.4%
NCT01646255 · Phase 3 · registry result, not featured evidence
4.8%
NCT01646268 · Phase 3 · registry result, not featured evidence
5.6%
NCT01723904 · Phase 3 · registry result, not featured evidence
10.6%
NCT01631825 · Phase 3 · registry result, not featured evidence
0%8 mg/24 hr
NCT00522379 · Phase 3 · registry result, not featured evidence
1.9%6 mg/24 hr
NCT00522379 · Phase 3 · registry result, not featured evidence
2.8%4 mg/24 hr
NCT00522379 · Phase 3 · registry result, not featured evidence
4%2 mg/24 hr
NCT00522379 · Phase 3 · registry result, not featured evidence
5.2%
NCT00474058 · Phase 3 · registry result, not featured evidence
37.5%
NCT00501969 · Phase 3 · registry result, not featured evidence
24.2%
NCT00505687 · Phase 3 · registry result, not featured evidence
64%
NCT00594386 · Phase 3 · registry result, not featured evidence
34.5%
NCT00599196 · Phase 3 · registry result, not featured evidence
47.2%
NCT00594165 · Phase 3 · registry result, not featured evidence
0%
NCT00593606 · Phase 3 · registry result, not featured evidence
16.8%
NCT01628965 · Phase 2/3 · registry result, not featured evidence
2.2%
NCT00537485 · Phase 2/3 · registry result, not featured evidence
13.1%
NCT01631812 · Phase 2 · registry result, not featured evidence
3.4%
NCT01628848 · Phase 2 · registry result, not featured evidence
0%1 Puff
NCT00296192 · Phase 2 · registry result, not featured evidence
5.9%2 Puffs
NCT00296192 · Phase 2 · registry result, not featured evidence
0%3 Puffs
NCT00296192 · Phase 2 · registry result, not featured evidence
5.9%4 Puffs
NCT00296192 · Phase 2 · registry result, not featured evidence
7%Advanced Parkinson's Disease
NCT01634243 · Phase 2 · registry result, not featured evidence
4.8%Early-stage Parkinson's Disease
NCT01634243 · Phase 2 · registry result, not featured evidence
0%
NCT00292227 · Phase 1 · registry result, not featured evidence
—
Most frequent reported AEs
a
application site reaction 54.2% (placebo 11.8%)
nasopharyngitis 16.7% (placebo 15.3%)
dyskinesia 16.1% (placebo 1.2%)
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 33 more results
nausea 22.8% (placebo 7.7%)
dizziness 15.2% (placebo 12.8%)
suicidal ideation 11.4% (placebo 11.2%)
NCT01523301 · Phase 4 · registry result, not featured evidence
high dose
somnolence 9.8% (placebo 7.5%)
constipation 7.3% (placebo 2.5%)
dry mouth 7.3% (placebo 0%)
NCT01782222 · Phase 4 · registry result, not featured evidence
low dose
application site pruritus 9.8% (placebo 5%)
depression 9.8% (placebo 5%)
nausea 9.8% (placebo 10%)
NCT01782222 · Phase 4 · registry result, not featured evidence
nausea 22.9% (placebo 6.1%)
headache 17.1% (placebo 12.1%)
application site erythema 8.6% (placebo 0%)
NCT01744496 · Phase 4 · registry result, not featured evidence
application site pruritus 10.3%
application site erythema 6.9%
dizziness 6.9%
NCT01711866 · Phase 4 · registry result, not featured evidence
nausea 12.1% (placebo 5.6%)
somnolence 8.1% (placebo 5.6%)
application site pruritus 6.7% (placebo 1.6%)
NCT01300819 · Phase 4 · registry result, not featured evidence
procedural pain 35.7%
constipation 21.4%
nausea 21.4%
NCT00594464 · Phase 4 · registry result, not featured evidence
dizziness 10.9% (placebo 4.1%)
nausea 9.2% (placebo 1.2%)
pruritus 8% (placebo 5.8%)
NCT01646255 · Phase 3 · registry result, not featured evidence
nausea 8.9% (placebo 3.3%)
dizziness 8.1% (placebo 5.7%)
pruritus 8.1% (placebo 4.1%)
NCT01646268 · Phase 3 · registry result, not featured evidence
application site pruritus 13.3%
dizziness 10%
orthostatic hypotension 10%
NCT01723904 · Phase 3 · registry result, not featured evidence
application site reaction 61.7%
nasopharyngitis 23.7%
dyskinesia 15.6%
NCT01631825 · Phase 3 · registry result, not featured evidence
8 mg/24 hr
dyskinesia 14.9% (placebo 2.8%)
nausea 11.7% (placebo 7.4%)
headache 8.5% (placebo 11.1%)
NCT00522379 · Phase 3 · registry result, not featured evidence
6 mg/24 hr
nausea 14.4% (placebo 7.4%)
dyskinesia 10.6% (placebo 2.8%)
application site pruritus 7.7% (placebo 1.9%)
NCT00522379 · Phase 3 · registry result, not featured evidence
4 mg/24 hr
dizziness 10.3% (placebo 8.3%)
nausea 10.3% (placebo 7.4%)
headache 7.5% (placebo 11.1%)
NCT00522379 · Phase 3 · registry result, not featured evidence
2 mg/24 hr
nausea 12.9% (placebo 7.4%)
headache 9.9% (placebo 11.1%)
dizziness 7.9% (placebo 8.3%)
NCT00522379 · Phase 3 · registry result, not featured evidence
nausea 21.5% (placebo 9.4%)
dizziness 10.5% (placebo 6.3%)
dyskinesia 7.9% (placebo 4.2%)
NCT00474058 · Phase 3 · registry result, not featured evidence
somnolence 33.7%
fall 15.4%
dyskinesia 13.9%
NCT00501969 · Phase 3 · registry result, not featured evidence
somnolence 28%
oedema peripheral 19.4%
fall 15.6%
NCT00505687 · Phase 3 · registry result, not featured evidence
somnolence 58.1%
fall 38.8%
oedema peripheral 31%
NCT00594386 · Phase 3 · registry result, not featured evidence
somnolence 38.4%
nausea 18.9%
oedema peripheral 18.7%
NCT00599196 · Phase 3 · registry result, not featured evidence
somnolence 53.7%
oedema peripheral 36.6%
fall 31.9%
NCT00594165 · Phase 3 · registry result, not featured evidence
dizziness 6%
tremor 6%
asthenia 5.2%
NCT00593606 · Phase 3 · registry result, not featured evidence
application site reaction 67.1%
nausea 32.9%
nasopharyngitis 18.2%
NCT01628965 · Phase 2/3 · registry result, not featured evidence
application site reaction 46.7% (placebo 22.2%)
nausea 23.3% (placebo 5.6%)
vomiting 15.6% (placebo 1.1%)
NCT00537485 · Phase 2/3 · registry result, not featured evidence
application site reaction 51.5%
nasopharyngitis 20.8%
dyskinesia 16.2%
NCT01631812 · Phase 2 · registry result, not featured evidence
application site reaction 50.6% (placebo 18.4%)
nasopharyngitis 20.7% (placebo 14.9%)
nausea 19.5% (placebo 5.7%)
NCT01628848 · Phase 2 · registry result, not featured evidence
1 Puff
somnolence 11.8% (placebo 7.7%)
application site dryness 5.9% (placebo 0%)
application site irritation 5.9% (placebo 0%)
NCT00296192 · Phase 2 · registry result, not featured evidence
2 Puffs
application site reaction 17.6% (placebo 0%)
somnolence 11.8% (placebo 7.7%)
back pain 5.9% (placebo 0%)
NCT00296192 · Phase 2 · registry result, not featured evidence
3 Puffs
somnolence 16.7% (placebo 7.7%)
application site irritation 11.1% (placebo 0%)
dizziness 5.6% (placebo 7.7%)
NCT00296192 · Phase 2 · registry result, not featured evidence
4 Puffs
dizziness 17.6% (placebo 7.7%)
nausea 17.6% (placebo 15.4%)
application site reaction 11.8% (placebo 0%)
NCT00296192 · Phase 2 · registry result, not featured evidence
administration site reaction 46.5%
nausea 20.9%
somnolence 16.3%
NCT01634243 · Phase 2 · registry result, not featured evidence
administration site reaction 76.2%
nausea 38.1%
nasopharyngitis 28.6%
NCT01634243 · Phase 2 · registry result, not featured evidence
nausea 42.4% (placebo 21.9%)
dizziness 28.8% (placebo 9.4%)
headache 28.8% (placebo 25%)
NCT00292227 · Phase 1 · registry result, not featured evidence
—

Notes

  1. aPopulation comparability has not been reviewed for 33 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

rotigotine

UPDRS Part III -10.9 vs -4.5 placebo score @ 16wk
absolute change · score
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 3 more results
-9.7 vs -5.5 placebo score @ 8wk
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-9.9 vs -5.3 placebo score @ 10wk
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
-10.1 vs -4.4 placebo score @ 12wk
NCT01628848 · Phase 2 · registry result, not featured evidence
UPDRS Part 2 -3.6 vs -1.3 placebo score @ 16wk
absolute change · score
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF-time Change -1.3 vs -0.4 placebo per day @ 16wk
absolute change · per day
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
PDSS-2 -3.1 vs -1.8 placebo score @ 16wk
absolute change · score
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
On Time Change 1.3 vs 0.2 placebo per day @ 16wk
absolute change · per day
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
On Time Without Troublesome Dyskinesia Change 1.1 vs 0.3 placebo per day @ 16wk
absolute change · per day
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
On Time With Troublesome Dyskinesia Change 1.3 vs -0.2 placebo hours @ 16wk
absolute change · hours
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
CGI-I 50.3% (n=163) vs 30.9% (n=81) placebo @ 16wk
responder rate · % of participants
Decreased
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Early Morning Dystonia 10.4% (n=163) vs 7.4% (n=81) placebo @ 16wk
responder rate · % of participants
Decreased
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Daytime Dystonia 8.6% (n=163) vs 3.7% (n=81) placebo @ 16wk
responder rate · % of participants
Decreased
NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
AASIS -4.6 vs -4.4 placebo score @ 19wklow dose
absolute change · score
Maintenance
NCT01782222 · Phase 4 · registry result, not featured evidence
show 3 more results
-4.9 vs -4.4 placebo score @ 19wkhigh dose
NCT01782222 · Phase 4 · registry result, not featured evidence
-4.8 vs -1.5 placebo score @ 19wklow dose
NCT01782222 · Phase 4 · registry result, not featured evidence
-5.5 vs -1.5 placebo score @ 19wkhigh dose
NCT01782222 · Phase 4 · registry result, not featured evidence
UPDRS II, III -12.4 vs -4.8 placebo score @ 19wklow dose
absolute change · score
Maintenance
NCT01782222 · Phase 4 · registry result, not featured evidence
show 3 more results
-10.7 vs -4.8 placebo score @ 19wkhigh dose
NCT01782222 · Phase 4 · registry result, not featured evidence
-8.3 vs -5.1 placebo score
NCT01744496 · Phase 4 · registry result, not featured evidence
-4.9 vs -0.2 placebo score @ 24wk
NCT01646268 · Phase 3 · registry result, not featured evidence

+ 80 further endpoints in the CSV export.

Rotigotine (LY03003)

UPDRS Part II III -11.8 vs -5.6 placebo score
absolute change · score
NCT04571164 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: rotigotine's landscape · Rotigotine (LY03003)'s landscape